Intranet PAC-CI
Published on 29 Sep 2022

INTENSE-TBM Project General Assembly

PAC-CI

Researcher, PAC-CI

666 Views
INTENSE-TBM Project General Assembly

Summary & Key Points

"The meeting began with a scientific update. Several recent publications reinforce our decision to use high-dose oral rifampin, including oral versus IV..."

The meeting began with a scientific update. Several recent publications reinforce our decision to use high-dose oral rifampicin, including oral versus IV administration. Regarding the study’s progress, 218 patients have been enrolled to date, 19 of whom are in the PK substudy. Very few follow-up visits are missing. Deaths occur primarily during the first 3 months. Each country presented the challenges it has faced in terms of recruitment. In South Africa, many patients are classified as Grade 1 because no family members can be located. The South African team has requested authorization to enroll patients without consent. The ANRS has requested a vote from the General Assembly. The protocol has been submitted to Trials.

 

PAC-CI

Associate researcher at PAC-CI, contributing to the advancement of scientific research and public health in Côte d'Ivoire.

Contact the author

Related Articles